NVS - Novartis AG

NYSE - NYSE Delayed price. Currency in USD
Show:
Income statement
Balance sheet
Cash flow
Annual

Income statement

All numbers in thousands
Breakdown
ttm
31/12/2019
31/12/2018
31/12/2017
31/12/2016
Total revenue
49,930,000
48,677,000
53,166,000
50,135,000
49,436,000
Cost of revenue
14,896,000
14,425,000
18,407,000
17,175,000
17,520,000
Gross profit
35,034,000
34,252,000
34,759,000
32,960,000
31,916,000
Operating expenses
Research development
9,163,000
9,402,000
9,074,000
8,972,000
9,039,000
Selling general and administrative
14,525,000
14,369,000
16,471,000
14,997,000
14,192,000
Total operating expenses
25,446,000
25,166,000
26,590,000
24,331,000
23,648,000
Operating income or loss
9,588,000
9,086,000
8,169,000
8,629,000
8,268,000
Interest expense
863,000
850,000
957,000
777,000
707,000
Total other income/expenses net
542,000
499,000
6,372,000
1,062,000
233,000
Income before tax
9,421,000
8,940,000
13,835,000
8,999,000
7,817,000
Income tax expense
1,969,000
1,793,000
1,221,000
1,296,000
1,119,000
Income from continuing operations
7,452,000
7,147,000
12,614,000
7,703,000
6,698,000
Net income
12,142,000
11,732,000
12,611,000
7,703,000
6,712,000
Net income available to common shareholders
12,142,000
11,732,000
12,611,000
7,703,000
6,712,000
Basic EPS
-
5.12
5.44
3.28
2.82
Diluted EPS
-
5.06
5.38
3.25
2.80
Basic average shares
-
2,291,000
2,319,000
2,346,000
2,378,000
Diluted average shares
-
2,319,000
2,344,000
2,371,000
2,400,000
EBITDA
-
15,616,000
21,684,000
15,852,000
14,567,000